Janus kinase signal transducer–activator of transcription pathway therapies are capable of restoring pigmentation in patients with vitiligo, but the field of Dermatology has struggled to agree on what it means when that pigmentation is lost again and treatment strategies that may be effective in restoring pigmentation.
That gap is the focus of an Editorial by Stanca Birlea, MD, PhD, of the Anastasios Medical Center in Romania. Despite a wave of therapeutic advances—including trials of ruxolitinib, povorcitinib, and upadacitinib — vitiligo has lacked standardized definitions of severity and relapse. Clinical studies have used different instruments, inconsistent Vitiligo Area Scoring Index thresholds, and relapse definitions ranging from any loss of pigmentation to investigator judgment without formal criteria. As a result, comparisons across studies are limited, meta-analyses are less likely to identify clinically meaninful treatment effects, and decisions for systemic therapies are less standardized.
The Editorial accompanies an international consensus statement published by Eleftheriadou et al in JAMA Dermatology that aimed to establish body surface area–based severity strata and define relapse as loss of pigmentation in previously repigmented lesions after 3 months or longer—regardless of whether repigmentation occurred spontaneously or with treatment.
Dr. Birlea underscored that the lack of standardization hasn't just been a research inconvenience. It has complicated efforts to determine which patients should receive treatment, how aggressively they should be treated, and how treatment response should be measured. Without harmonized relapse and maintenance data, the long-term benefits of newer therapies remain difficult to fully characterize.
Durability remains an open question. Dr. Birlea noted that only a few recent JAK inhibitor trials have directly assessed relapse, often in small samples. She added that those findings require confirmation in larger studies.
Although the consensus framework is a starting point, it isn't a final answer. As Dr. Birlea wrote, it represents “a conceptual and practical shift”—moving beyond single-metric scoring toward a multidimensional assessment that incorporates psychologic and clinical factors.
For clinicians managing patients with vitiligo, the criteria outlined by Eleftheriadou et al may offer a more consistent structure for assessing severity, tracking relapse, and informing treatment decisions. With the framework now in place, the next challenge becomes applying it consistently in both trials and practice.
The Editorial author declared that they have no competing interests.
Source: JAMA Dermatology
